This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Turner, A.P. Articles by Haselkorn, J.K. Search for Related Content PubMed PubMed Citation Articles by Turner, A.P. Articles by Haselkorn, J.K. Pubmed/NCBI databases Medline Plus Health Information Healthy Living Multiple Sclerosis Social Bookmarking                         What's this?

Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model

VA Puget Sound Health Care System, VA Multiple Sclerosis Center of Excellence West, VA Center of Excellence in Substance Abuse Treatment and Education, Department of Rehabilitation Medicine, University of Washington, WA, USA, Aaron.Turner{at}va.gov

D.R. Kivlahan

VA Puget Sound Health Care System, VA Center of Excellence in Substance Abuse Treatment and Education, Department of Psychiatry and Behavioral Sciences, University of Washington, WA, USA

A.P. Sloan

VA Puget Sound Health Care System, VA Multiple Sclerosis Center of Excellence West

J.K. Haselkorn

VA Puget Sound Health Care System, VA Multiple Sclerosis Center of Excellence West, Department of Rehabilitation Medicine, University of Washington, WA, USA, Department of Epidemiology, University of Washington, WA, USA

Objective To evaluate ongoing adherence to disease modifying therapies (DMT) among individuals with multiple sclerosis and test the utility of the Health Beliefs Model (HBM) to predict adherence.

Design Telephone survey completed at baseline with monthly telephone follow-up for 6 months.

Setting Veterans Health Administration.

Participants Eighty-nine veterans with MS actively enrolled in a regional VA MS outpatient clinic currently prescribed DMT.

Measures Demographic information. Selected items from the Adherence Determinants Questionnaire (ADQ) and Barriers to Care Scale (BACS).

Results Adherence in this population of ongoing DMT users was relatively high (over 80% achieved 80% adherence at follow-up time points). Logistic regression and hierarchical multiple regression analyses controlling for demographics and disease duration were employed to examine the relationship of HBM constructs of perceived susceptibility, severity, benefits, and barriers to DMT adherence and satisfaction at 2-, 4- and 6-month follow-up. Of the four HBM constructs, only perceived benefits uniquely predicted both outcomes across multiple time points.

Conclusion Sustained adherence to DMT remains a challenge for an important minority of individuals with MS. The Health Beliefs Model provides insight into psychosocial mechanisms that maintain adherence behavior. In particular, focus upon the perceived benefits of ongoing DMT therapy may be a promising focus for future interventions. Multiple Sclerosis 2007; 13: 1146—1152. http://msj.sagepub.com

Key Words: health beliefs • medication adherence • multiple sclerosis

References

• Burks JS A practical approach to immunomodulatory therapy for multiple sclerosis. Phys Med Rehabil Clin N Am 2005; 16: 449—66.[Medline] [Order article via Infotrieve]
• Mohr DC, Goodkin DE, Masuoka L., Dick LP, Russo D., Eckhardt J. et al. Treatment adherence and patient retention in the first year of a Phase-III clinical trial for the treatment of multiple sclerosis. Multiple Sclerosis 1999; 5: 192—97.[Abstract/Free Full Text]
• Hadjimichael O., Volmer TL Adherence to injection therapy in multiple sclerosis: Patients survey. Neurology 1999; 53: 1190—97.[Abstract/Free Full Text]
• Becker MH, Maiman LA Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 1975; 13: 10—24.[Web of Science][Medline] [Order article via Infotrieve]
• Aiken LS, West SG, Woodward CK, Reno RR Health beliefs and compliance with mammography-screening recommendations in asymptomatic women. Health Psychol 1994; 13: 122—29.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Arneson SW, Triplett JL, Hahnemann B., Merington E. Factors affecting parental use of child automobile safety restraints. Child Health Care 1985; 13: 181—86.[CrossRef]
• Cerkoney KA, Hart LK The relationship between the Health Belief Model and compliance of persons with diabetes mellitus. Diabetes Care 1980; 3: 594—98.[Abstract]
• Simonds JF, Goldstein D., Kilo C., Hoette S. The role of health beliefs in the regimen adherence and metabolic control of adolescents and adults with diabetes mellitus. J Consult Clin Psychol 1987; 55: 139—44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hershey JC, Morton BG, Davis JR, Reichgott MJ Patient compliance with antihypertensive medication. Am J Public Health 1980; 70: 1081—89.[Abstract/Free Full Text]
• Vollmer TL, Hadjimichael O., Preiningerova J., Ni W., Buenconsejo J. Disability and treatment patterns of multiple sclerosis patients in United States: A comparison of veterans and nonveterans. J Rehabil Res Dev 2002; 39: 163—74.[Web of Science][Medline] [Order article via Infotrieve]
• Beatty WW, Paul RH, Wilbanks SL, Hames KA, Blanco CR Identifying multiple sclerosis patients with mild or global cognitive impairment using the Screening Examination for Cognitive Impairment. Neurology 1995; 45: 718—23.[Abstract/Free Full Text]
• DiMatteo MR, Hays RD, Gritz ER, Roshan B. Patient adherence to cancer control regimens: Scale development and initial validation. Psychol Assess 1993; 5: 102—12.[CrossRef]
• Schwartz C., Vollmer TL, Lee H. Reliability and validity of two self-report measures of impairment and disability for MS. Neurology 1999; 52: 63—70.[Abstract/Free Full Text]
• Heckman TG, Somlai AM, Peters J., Walker J., Otto-Salaj L., Galdabini CA et al. Barriers to care among persons living with HIV/AIDS in urban and rural areas. AIDS Care 1998; 10: 365—75.[Web of Science][Medline] [Order article via Infotrieve]
• Stone VE Strategies for optimizing adherence to highly active antiretroviral therapy: lessons from research and clinical practice. Clin Infect Dis 2001; 33: 865—72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Haynes RB, McKibbon KA, Kanani R. Systematic review of randomized trials of interventions to assist patients to follow prescriptions for medications. Lancet 1997; 348: 383—86.[Web of Science]
• Rogers PG, Bullman WR Prescription medicine compliance: A review of the baseline of knowledge. A report of the National Council on Patient Information and Education. Journal of Pharmacoepidemiology 1995; 2: 3.
• Roter DL, Hall JA, Merisca R., Nordstrom B., Cretin D., Svarstad B. Effectiveness of interventions to improve patient compliance: A meta-analysis. Med Care 1998; 36: 1138—61.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Osterberg L., Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487—97.[Free Full Text]
• Haynes RB, McDonald HP, Garg AX Helping patients follow prescribed treatment. JAMA 2002; 288: 2880—83.[Abstract/Free Full Text]
• Mohr DC, Boudewyn AC, Likosky W., Levine E., Goodkin DE Injectable medication for the treatment of multiple sclerosis: The influence of self-efficacy expectations and injection anxiety on adherence and ability to self-inject. Ann Behav Med 2001; 23: 125—32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fraser C., Hadjimichael O., Volmer TL Predictors of adherence to glatiramer acetate therapy in individuals with self-reported progressive forms of multiple sclerosis. J Neurosci Nurs 2003; 35: 163—74.[Medline] [Order article via Infotrieve]
• Harrison JA, Mullen PD, Green LW A meta-analysis of studies of the health belief model with adults. Health Educ Res 1992; 7: 107—16.[Abstract/Free Full Text]
• Tremlett HL, Oger JO Interrupted therapy: Stopping and switching of the beta-interferons prescribed for MS. Neurology 2003; 61: 551—54.[Abstract/Free Full Text]

Multiple Sclerosis, Vol. 13, No. 9, 1146-1152 (2007)
DOI: 10.1177/1352458507078911


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Turner, A.P. Articles by Haselkorn, J.K. Search for Related Content PubMed PubMed Citation Articles by Turner, A.P. Articles by Haselkorn, J.K. Pubmed/NCBI databases Medline Plus Health Information Healthy Living Multiple Sclerosis Social Bookmarking                         What's this?